高级检索
当前位置: 首页 > 详情页

Correlation between IGF2BP2 gene polymorphism and the risk of breast cancer in Chinese Han women

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Hebei Med Univ, Hosp 4, Dept Endocrinol, Shijiazhuang 050011, Peoples R China [2]Hebei Med Univ, Dept Immunol, Key Lab Immune Mech & Intervent Serious Dis Hebei, Shijiazhuang 050017, Peoples R China [3]Bethune Int Peace Hosp, Dept Med Oncol, Shijiazhuang 050082, Peoples R China [4]First Hosp Shijiazhuang City, Dept Med Oncol, Shijiazhuang 050011, Peoples R China
出处:
ISSN:

关键词: Single nucleotide polymorphism IGF2BP2 gene Breast cancer

摘要:
Objective: To investigate the correlations between the polymorphism of IGF2BP2, a diabetes predisposing gene, and breast cancer risk in Chinese female with Han nationality. Method: The genomic DNAs were extracted from the peripheral blood drawn from 564 female breast cancer patients and 394 healthy females of Han nationality. The polymorphism of IGF2BP2 gene rs4402960 was detected by a multiplex PCR-Ligase detection reaction (PCR-LDR) assay from genomic DNA. The correlations between genotype and breast cancer risk as well as clinicopathologic characteristics were compared. Results: The differences are significant between genotype distribution of IGF2BP2 gene rs4402960 (P = 0.009) and allele gene frequency from both disease and control groups. Both T gene carriers (GT + TT) (OR = 1.462; 95% CI, 1.127-1.897) and T allele gene (OR = 1.382; 95% CI, 1.116-1.710) significantly increase the risk of breast cancer. No considerable correlations were observed between the polymorphism of rs4402960 and the clinical pathological parameters, such as age at diagnosis, lymphatic metastasis, estrogen and progesterone receptor status, cerb-B2 receptor status, and tumor staging. Conclusions: The IGF2BP2 gene rs4402960 polymorphism increases the breast cancer risk of Chinese females with Han nationality, and is a breast cancer predisposing gene. (C) 2014 Elsevier Masson SAS. All rights reserved.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2015]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验 4 区 药学
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 医学:研究与实验 2 区 药学
JCR分区:
出版当年[2015]版:
Q3 MEDICINE, RESEARCH & EXPERIMENTAL Q3 PHARMACOLOGY & PHARMACY
最新[2024]版:
Q1 MEDICINE, RESEARCH & EXPERIMENTAL Q1 PHARMACOLOGY & PHARMACY

影响因子: 最新[2024版] 最新五年平均 出版当年[2015版] 出版当年五年平均 出版前一年[2014版] 出版后一年[2016版]

第一作者:
第一作者机构: [1]Hebei Med Univ, Hosp 4, Dept Endocrinol, Shijiazhuang 050011, Peoples R China
通讯作者:
通讯机构: [2]Hebei Med Univ, Dept Immunol, Key Lab Immune Mech & Intervent Serious Dis Hebei, Shijiazhuang 050017, Peoples R China [3]Bethune Int Peace Hosp, Dept Med Oncol, Shijiazhuang 050082, Peoples R China [*1]Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei Province, Department of Immunology, Hebei Medical University, Shijiazhuang 050017, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:42316 今日访问量:0 总访问量:1365 更新日期:2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号